课题基金 / 基金详情

Per2调控心肌细胞自噬在β1肾上腺素受体自身抗体诱导心房纤维化及房颤中的作用机制

批准号:
82100343
项目类别:
青年科学基金项目(C类)
资助金额:
30.0 万元
负责人:
商鲁翔
依托单位:
学科分类:
心电活动异常与心律失常
结题年份:
2024
批准年份:
2021
项目状态:
已结题
项目参与者:
商鲁翔

项目摘要

结项摘要

相似基金

相关文献

中文摘要
心房纤维化与心房颤动(房颤)发生发展密切相关。课题组前期研究发现β1肾上腺素受体自身抗体(β1ARAb)表达增强诱导心房纤维化、增加房颤易感性,但其具体机制不明。申请人通过蛋白组学等预实验进一步发现:免疫β1ARAb可导致心房肌细胞自噬降低、凋亡增加,并下调左心房Period2(Per2)及其下游蛋白PTEN表达;而Per2转染至β1ARAb孵育的HL-1细胞,可恢复β1ARAb诱导的自噬及凋亡相关蛋白的表达变化。基于前期研究证据,我们推测β1ARAb通过抑制Per2/PTEN表达、激活PI3K/AKT/mTOR信号通路、降低心肌细胞自噬,最终导致心房纤维化及房颤。本课题拟采用被动免疫兔模型及HL-1细胞,通过在体和离体层面观察双向调控Per2对β1ARAb诱导的心房电生理及心肌细胞自噬、凋亡的影响,探索β1ARAb诱导心房纤维化及房颤的分子机制,为房颤精准治疗提供新的干预靶点。
英文摘要
Atrial fibrosis is closely related to the occurrence and development of atrial fibrillation (AF). Our previous studies have found that the expression of β1-adrenoceptor autoantibody (β1ARAB) could increase the induction of atrial fibrosis and susceptibility to AF, but the detailed mechanism remained to be clarified. Through proteomics and other pre-experiments, the applicant further found that the immunity of β1ARAb can reduce autophagy and increase apoptosis of atrial myocytes, the protein expression of Period2 (Per2) and PTEN in the left atrium were down-regulated by β1ARAb, while the expression of autophagy and apoptosis-related proteins induced by β1ARAb could be restored by Per2 transfection into HL-1 cells incubated with β1ARAb. Based on the previous evidence, we speculate that β1ARAb activates the PI3K/AKT/mTOR signaling pathway by inhibiting the expression of Per2/PTEN, reduces autophagy in cardiomyocytes, and ultimately leads to the occurrence of AF. In this study, we use rabbit model and HL-1 cells to observe the effects of bi-directional regulation of Per2 on atrial electrophysiology and cardiomyocyte autophagy and apoptosis induced by β1ARAb in vivo and in vitro, and to explore the molecular mechanism of β1ARAb-induced atrial fibrosis and AF, and to provide a new molecular target for precise treatment of AF.
β1肾上腺素受体自身抗体(β1AAb)已被证实与房颤的发生和维持密切相关。本研究通过构建β1AAb主动免疫动物和细胞模型,系统探讨其在房颤发病中的病理机制,并评估多靶点干预策略的有效性。研究结果显示,高表达β1AAb显著缩短心房有效不应期,降低心房传导速度,并增加房颤发生率及持续时间,伴随心房电传导不均一性加剧。机制研究表明,β1AAb通过激活CaMKII2α/RyR2轴,诱导钙稳态失衡,表现为钙瞬变恢复速率降低及RyR2不应期空间异质性增加。此外,β1AAb加剧线粒体形态异常及功能损伤,并通过抑制PGC-1α和TFAM,阻碍线粒体生物发生,进一步加重心房结构重塑。同时,β1AAb诱导自噬抑制和细胞凋亡增加,共同促进房颤的发生和维持。. 针对这些病理变化,本研究通过比索洛尔(β1受体阻滞剂)、Oroxin B(PTEN激活剂)和吡格列酮(PPAR-γ激动剂)的干预实验,验证了多靶点治疗的潜在作用。结果表明:比索洛尔能够有效改善心房电重塑,降低房颤的诱发率和持续时间;Oroxin B通过激活PTEN信号轴,抑制AKT/mTOR和NF-κB通路的过度活化,恢复自噬活性,并显著减少细胞凋亡;吡格列酮通过调控心房能量代谢,显著增加GLUT1、CPT1a等葡萄糖和脂肪酸代谢关键分子的表达,同时改善线粒体功能障碍及心房间质纤维化。. 本研究揭示了β1AAb在房颤发病中的重要作用机制,明确了PTEN、CaMKII2α/RyR2轴和PPAR-γ等关键分子在房颤病理中的调控作用,为自身免疫性房颤的防治提供了重要的理论依据。本研究为未来开发针对β1AAb相关通路的房颤精准治疗方案提供了实验基础,并为房颤的诊断、风险预测和个体化治疗拓展了新思路。
国内基金
海外基金